Hagop Kantarjian: Chemo-free regimens are highly effective in Ph+ALL

Hagop Kantarjian shared on X/Twitter:

“Chemo-free regimens (TKIs-blinatumomab) highly effective in Ph+ALL; may replace intensive chemotherapy and allo SCT in most such patients in the future.
Clinical Lymphoma, Myeloma and Leukemia.”

Visit the article website.
Source: Hagop Kantarjian/X

Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine. Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades.

His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib. Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.